This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Pharmacokinetic, Efficacy and Safety of BT524 in P...
Clinical trial

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

Read time: 3 mins
Last updated:1st Mar 2013
Identifier: NCT02065882

Brief Summary:
The purpose of the study is to investigate pharmacokinetics, efficacy and safety of BT524 in patients with congenital fibrinogen deficiency.

Detailed Description:
The present study is designed as a prospective, open-label, multicentre, phase I/III study investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524 following intravenous administration in the treatment or prophylaxis of bleeding in patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 36 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open-label, Phase I/III Study Investigating Pharmacokinetic Properties of BT524 and Efficacy and Safety of BT524 in the Treatment and Prophylaxis of Bleeding in Patients With Congenital Fibrinogen Deficiency
Study Start Date: March 2013
Estimated Primary Completion Date: March 2020
Estimated Study Completion Date: November 2020

Arm:
- Experimental:
BT524

Category Value
Date last updated at source 2019-07-25
Study type(s) Interventional
Expected enrolment 36
Study start date 2013-03-01
Estimated primary completion date 2020-03-01

View full details